Advances in rotavirus molecular biology have enabled the development of new vaccine candidates, including those using genetic reassortment.
Answers are grounded in this paper and cite their sources.
Should not yet alter rotavirus vaccination practices; leaves open translation of molecular advances into proven clinical benefit.
The first candidate rotavirus vaccine was a live attenuated oral vaccine made by the classical empirical method of serial passage of virus in tissue culture cells. Current tetravalent vaccine candidates that are in the final stages of efficacy testing in the United States were made by genetic reassortment. This article briefly highlights how advances in the basic understanding of the molecular biology of rotaviruses have facilitated vaccine development. New approaches for second-generation vaccines and improvements in vaccine efficacy based on further exploitation of the tools and knowledge of rotavirus molecular biology and pathogenesis are discussed.
No takes yet. Share an insight, caveat, or question.
Mary K. Estes (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: